Novartis drops Aurograb
This article was originally published in Scrip
Executive Summary
Novartishas discontinued development of the novel antibacterial antibody product Aurograb following disappointing results in Phase II studies. As a result, the firm's pharmaceuticals division will take a $235 million impairment charge in the third quarter, which reflects the full amount allocated to this project.